Approaches for Transitioning to Multidisciplinary Cancer Care Teams
Mark S. Soberman, MD, MBA, FACS, 2017-2018 president of the Association of Community Cancer Centers (ACCC), discusses various approaches that can be used to integrate multidisciplinary healthcare programs into various healthcare settings, following a panel discussion during the ACCC 44th Annual Meeting & Cancer Center Business Summit.
Mark S. Soberman, MD, MBA, FACS, 2017-2018 president of the Association of Community Cancer Centers (ACCC), discusses various approaches that can be used to integrate multidisciplinary healthcare programs into various healthcare settings, following a panel discussion during the ACCC 44th Annual Meeting & Cancer Center Business Summit. A multidisciplinary cancer care program can help in better meeting the needs of patients with cancer by integrating a number of specialists into the determination of a whole course of treatment for a patient.
There are 3 important steps to introducing an integrated cancer care system into any setting. First, this cannot be managed unless there is a will to do so, Soberman said. Understanding the importance of an integrated cancer care team can help in convincing providers that this is important.
Second, having a champion on the team who is already passionate about this will impact the transition process. Having even 1 person join the team who is already passionate about multidisciplinary cancer care can be a key element to a smooth transition, Soberman explained.
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
